COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study.
Adverse effects
COVID-19
Disease flare
Vaccination
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
15
09
2021
accepted:
22
10
2021
pubmed:
6
11
2021
medline:
27
1
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
To describe the rate and type of adverse effects (AEs) and the frequency of disease flares after COVID-19 vaccination and to assess the reasons for vaccination hesitancy (non-vaccination) in SRD patients. Telephone interviews were conducted of SRD patients consecutively enrolled (15/06/2021-1/7/2021). Participants were asked about the type of AEs and disease flare after vaccination. Reasons for vaccination hesitancy were recorded. Univariate and mutivariable analyses examined associations of demographic, clinical and other features, with occurrence of AEs, disease flare and non-vaccination. For the latter, association with negative vaccination behaviour (not influenza vaccinated for the last 2 years) and nocebo-prone behaviour (denoting AEs attributed to negative expectations [Q-No questionnaire]) was also tested. 561 out of 580 contacted patients were included in the study. 441/561 (78.6%) patients were vaccinated [90% (Pfizer, Moderna), 10% (Astra-Zeneca)]. AEs were reported by 148/441 (33.6%), with rates being comparable between the three vaccines. AEs were more common in females and those with chronic obstructive pulmonary disease [OR, 95% CI; females: 2.23 (1.30-3.83); COPD: 3.31 (1.24-8.83)]. Disease flare was reported in 9/441 (2%) patients. For those unvaccinated, fear that the vaccine would be harmful (53.3%), could cause disease flare (24.2%) and/or could cause thrombosis (21.7%) were the main reasons to do so. Multivariable analysis identified as independent variables for non-vaccination: nocebo-prone behaviour (OR; 95% CI, 3.88; 1.76-8.55), negative vaccination behaviour (6.56; 3.21-13.42) and previous COVID-19 infection (2.83; 1.13-7.05). Higher educational status was protective (0.49; 0.26-0.92). No new safety signals for COVID-19 vaccination were observed. Vaccination campaign should target SRD patients with nocebo-prone and negative influenza vaccination behaviour.
Identifiants
pubmed: 34739573
doi: 10.1007/s00296-021-05039-3
pii: 10.1007/s00296-021-05039-3
pmc: PMC8569844
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-39Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scire CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM, Alliance C-GR (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80:930–942. https://doi.org/10.1136/annrheumdis-2020-219498
doi: 10.1136/annrheumdis-2020-219498
pubmed: 33504483
Benucci M, Infantino M, Marotto D, Ardizzone S, Manfredi M, Sarzi-Puttini P (2021) Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives. Clin Exp Rheumatol 39:196–202
pubmed: 33555252
Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharouf F, Shefer G, Sharon O, Pel S, Nevo S, Elkayam O (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330–1338. https://doi.org/10.1136/annrheumdis-2021-220647
doi: 10.1136/annrheumdis-2021-220647
pubmed: 34127481
Geisen UM, Berner DK, Tran F, Sumbul M, Vullriede L, Ciripoi M, Reid HM, Schaffarzyk A, Longardt AC, Franzenburg J, Hoff P, Schirmer JH, Zeuner R, Friedrichs A, Steinbach A, Knies C, Markewitz RD, Morrison PJ, Gerdes S, Schreiber S, Hoyer BF (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80:1306–1311. https://doi.org/10.1136/annrheumdis-2021-220272
doi: 10.1136/annrheumdis-2021-220272
pubmed: 33762264
Ramirez GA, Della-Torre E, Moroni L, Yacoub MR, Dagna L, Group O-Cs (2021) Correspondence on “Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.” Ann Rheum Dis 80:e159. https://doi.org/10.1136/annrheumdis-2021-220539
doi: 10.1136/annrheumdis-2021-220539
pubmed: 34031031
Ruddy JA, Connolly CM, Boyarsky BJ, Werbel WA, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ (2021) High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 80:1351–1352. https://doi.org/10.1136/annrheumdis-2021-220656
doi: 10.1136/annrheumdis-2021-220656
pubmed: 34031032
Veenstra J, Wang J, McKinnon-Maksimowicz K, Liu T, Zuniga B, Hamzavi I, Zhou L, Mi QS (2021) Correspondence on “Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.” Ann Rheum Dis 80:e160. https://doi.org/10.1136/annrheumdis-2021-220736
doi: 10.1136/annrheumdis-2021-220736
pubmed: 34112654
Machingaidze S, Wiysonge CS (2021) Understanding COVID-19 vaccine hesitancy. Nat Med 27:1338–1339. https://doi.org/10.1038/s41591-021-01459-7
doi: 10.1038/s41591-021-01459-7
pubmed: 34272500
MacDonald NE, Hesitancy SWGoV (2015) Vaccine hesitancy: definition, scope and determinants. Vaccine 33:4161–4164. https://doi.org/10.1016/j.vaccine.2015.04.036
doi: 10.1016/j.vaccine.2015.04.036
pubmed: 25896383
Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, Costecalde C, Pijnenburg L, Fort J, Chatelus E, Sordet C, Javier RM, Gottenberg JE, Sibilia J, Fuentes-Silva Y, Arnaud L (2021) Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol 3:e243–e245. https://doi.org/10.1016/S2665-9913(21)00039-4
doi: 10.1016/S2665-9913(21)00039-4
pubmed: 33655219
pmcid: 7906671
Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, de Thurah A, Mueller-Ladner U, Paran D, Schreiber K, Warnatz K, Wulffraat NM, Elkayam O (2021) Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open 7:e001594. https://doi.org/10.1136/rmdopen-2021-001594
doi: 10.1136/rmdopen-2021-001594
pubmed: 33627440
Priori R, Pellegrino G, Colafrancesco S, Alessandri C, Ceccarelli F, Di Franco M, Riccieri V, Scrivo R, Sili Scavalli A, Spinelli FR, Conti F (2021) SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis 80:953–954. https://doi.org/10.1136/annrheumdis-2021-220059
doi: 10.1136/annrheumdis-2021-220059
pubmed: 33622689
Connolly CM, Ruddy JA, Boyarsky BJ, Avery RK, Werbel WA, Segev DL, Garonzik-Wang J, Paik JJ (2021) Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220231
doi: 10.1136/annrheumdis-2021-220231
pubmed: 34556484
Boekel L, Kummer LY, van Dam KPJ, Hooijberg F, van Kempen Z, Vogelzang EH, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G (2021) Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol 3:e542–e545. https://doi.org/10.1016/S2665-9913(21)00181-8
doi: 10.1016/S2665-9913(21)00181-8
pubmed: 34179831
pmcid: 8213359
Cherian S, Paul A, Ahmed S, Alias B, Manoj M, Santhosh AK, Varghese DR, Krishnan N, Shenoy P (2021) Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int 41:1441–1445. https://doi.org/10.1007/s00296-021-04917-0
doi: 10.1007/s00296-021-04917-0
pubmed: 34142203
Mitsikostas DD, Deligianni CI (2015) Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci 36:379–381. https://doi.org/10.1007/s10072-014-1959-2
doi: 10.1007/s10072-014-1959-2
pubmed: 25249398
Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A, Kravvariti E, Laskari K, Panopoulos S, Pappa M, Mitsikostas DD, Tektonidou MG, Sfikakis PP (2020) Nocebo-prone behaviour in patients with autoimmune rheumatic diseases during the COVID-19 pandemic. Mediterr J Rheumatol 31:288–294. https://doi.org/10.31138/mjr.31.3.288
doi: 10.31138/mjr.31.3.288
pubmed: 33196007
pmcid: 7656135
Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A, Kravvariti E, Laskari K, Panopoulos S, Pappa M, Tektonidou MG, Sfikakis PP (2020) Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217935
doi: 10.1136/annrheumdis-2020-217935
pubmed: 33268445
Esquivel-Valerio JA, Skinner-Taylor CM, Moreno-Arquieta IA, Cardenas-de la Garza JA, Garcia-Arellano G, Gonzalez-Garcia PL, Almaraz-Juarez FDR, Galarza-Delgado DA (2021) Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Rheumatol Int. https://doi.org/10.1007/s00296-021-05017-9
doi: 10.1007/s00296-021-05017-9
pubmed: 34622311
pmcid: 8496432
Bartels LE, Ammitzboll C, Andersen JB, Vils SR, Mistegaard CE, Johannsen AD, Hermansen MF, Thomsen MK, Erikstrup C, Hauge EM, Troldborg A (2021) Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 41:1925–1931. https://doi.org/10.1007/s00296-021-04972-7
doi: 10.1007/s00296-021-04972-7
pubmed: 34476603
Barbhaiya M, Levine JM, Bykerk VP, Jannat-Khah D, Mandl LA (2021) Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis 80:1352–1354. https://doi.org/10.1136/annrheumdis-2021-220732
doi: 10.1136/annrheumdis-2021-220732
pubmed: 34158370
Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, Calabrese C, Gravallese EM, Harpaz R, Kroger A, Sadun RE, Turner AS, Williams EA, Mikuls TR (2021) American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2. Arthritis Rheumatol 73:e30–e45. https://doi.org/10.1002/art.41877
doi: 10.1002/art.41877
pubmed: 34128356
pmcid: 8427105
Gaur P, Agrawat H, Shukla A (2021) COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey. Rheumatol Int 41:1601–1605. https://doi.org/10.1007/s00296-021-04938-9
doi: 10.1007/s00296-021-04938-9
pubmed: 34213580
Nikiphorou E, Alpizar-Rodriguez D, Gastelum-Strozzi A, Buch M, Pelaez-Ballestas I (2021) Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. Rheumatology (Oxford) 60:2040–2045. https://doi.org/10.1093/rheumatology/keaa840
doi: 10.1093/rheumatology/keaa840
Nikiphorou E, Lempp H, Kohrt BA (2019) Treatment failure in inflammatory arthritis: time to think about syndemics? Rheumatology (Oxford) 58:1526–1533. https://doi.org/10.1093/rheumatology/kez222
doi: 10.1093/rheumatology/kez222
Mitsikostas DD, Aravantinou-Fatorou KDC, Kravvariti EKE, Mylona MVP, Papagiannopoulou GDE-M, Dellis ATG, Dimopoulos MA, Amanzio M, Sfikakis PP (2021) Nocebo-prone behavior associated with SARS-CoV-2 vaccine hesitancy in healthcare workers. Vaccines. https://doi.org/10.3390/vaccines9101179
doi: 10.3390/vaccines9101179
pubmed: 34696287
pmcid: 8541064
Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP (2018) Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol 14:727–740. https://doi.org/10.1038/s41584-018-0110-9
doi: 10.1038/s41584-018-0110-9
pubmed: 30361674
Fragoulis GE, Grigoropoulos I, Mavrea E, Arida A, Bournia VK, Evangelatos G, Fragiadaki K, Karamanakos A, Kravvariti E, Panopoulos S, Pappa M, Thomas K, Tektonidou MG, Paraskevis D, Vassilopoulos D, Sfikakis PP (2021) Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the COVID-19 pandemic: a cross-sectional study. Rheumatol Int 41:895–902. https://doi.org/10.1007/s00296-021-04817-3
doi: 10.1007/s00296-021-04817-3
pubmed: 33661331
Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, Costecalde C, Pijnenburg L, Fort J, Chatelus E, Sordet C, Javier RM, Gottenberg JE, Sibilia J, Fuentes-Silva YJ, Arnaud L (2021) Cluster analysis reveals 3 main patterns of behavior towards SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. Rheumatology (Oxford) 60:S168–S176. https://doi.org/10.1093/rheumatology/keab432
doi: 10.1093/rheumatology/keab432
Yurttas B, Poyraz BC, Sut N, Ozdede A, Oztas M, Ugurlu S, Tabak F, Hamuryudan V, Seyahi E (2021) Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. Rheumatol Int 41:1105–1114. https://doi.org/10.1007/s00296-021-04841-3
doi: 10.1007/s00296-021-04841-3
pubmed: 33779780
Felten R, Kawka L, Dubois M, Ugarte-Gil MF, Fuentes-Silva Y, Piga M, Arnaud L (2021) Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol 3:e613–e615. https://doi.org/10.1016/S2665-9913(21)00221-6
doi: 10.1016/S2665-9913(21)00221-6
pubmed: 34312612
pmcid: 8294805
Woolf K, McManus IC, Martin CA, Nellums LB, Guyatt AL, Melbourne C, Bryant L, Gogoi M, Wobi F, Al-Oraibi A, Hassan O, Gupta A, John C, Tobin MD, Carr S, Simpson S, Gregary B, Aujayeb A, Zingwe S, Reza R, Gray LJ, Khunti K, Pareek M, Group U-RSC (2021) Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study. Lancet Reg Health Eur. https://doi.org/10.1016/j.lanepe.2021.100180
doi: 10.1016/j.lanepe.2021.100180
Mitsikostas DD, Belesioti I, Arvaniti C, Mitropoulou E, Deligianni C, Kasioti E, Constantinidis T, Dermitzakis M, Vikelis M, Hellenic Headache S (2017) Patients’ preferences for headache acute and preventive treatment. J Headache Pain 18:102. https://doi.org/10.1186/s10194-017-0813-3
doi: 10.1186/s10194-017-0813-3
pubmed: 28986900
pmcid: 5630539